The Europe genomics market size was estimated at USD 13.32 billion in 2025 to an estimated USD 60.82 billion by 2035, and is expanding at a CAGR of 16.40% from 2026 to 2035. Due to rising demand for personalized medicines, increasing genetic research funding, advancements in sequencing technologies, growing awareness of early disease detection and supportive government initiatives are also driving market growth across the region.

Technological progress in the European Genomics Market is driven by innovations like next generation sequencing, CRISPR- based gene editing and AI-powered biopharmaceutics tools. These advancements have reduced sequencing costs and improved data analysis speed and accuracy. Additionally, integration of high throughput platforms and digital infrastructure is enabling large-scale genomics studies, personalized medicine and faster drug discovery across the region.

Europe Genomics Market Share, By Country, 2025 (%)

• Spain - Due to advanced research infrastructure and consistent government support for scientific innovations, the country has built a solid foundation for genomics studies through investments in health care research skilled professionals and collaborative projects. This has encouraged steady growth in genomics research and development activities across Spain.
• Germany - Growth is likely driven by rising investments in life sciences, expanding research activities and increasing adoption of personalized medicines. Studying these factors can help predict future trends across the broader European Genomics markets.

Europe Genomics Market Share, By Application, 2025 (%)

• Functional Genomics - The segment dominated the market with a 32% share, due to its key role in understanding gene functions and disease mechanisms and supporting drug discovery and personalized medicine developments.
• Epigenomics - The segment accounted for 18% of the total market share, due to Growing used in studying gene regulation cancer research and identifying disease biomarkers for improved diagnosis and targeted therapies.
• Pathway Analysis - The segment accounted for 14% of the total market share, due to its ability to map biological pathways, helping resources understand disease mechanisms and develop targeted effective therapies.
• Biomarker Discovery - The segment accounted for 22% of the total market share, because it enables early disease detection, improves diagnostics accuracy and supports the development of targets and personalized treatment approaches.
• Others - The segment accounted for 14% of the total market share. It includes niche applications and emerging technologies that are still developing and have limited but growing adoption in research in health care.

Europe Genomics Market Share, By Deliverables, 2025 (%)

• Products - The segment dominated the market with a 70% share, due to high demand for sequencing instruments reagents and kids, which are essential for resource diagnostics and large scale genomics analysis applications.
• Services - The segment accounted for 30% of the total market share, due to rising outsourcing of sequencing data analysis and interpretation services by research institutes and health care organizations for cost efficiency and expertise.

Europe Genomics Market Share, By End-Use, 2025 (%)

• Pharmaceutical & Biotechnology Companies - The segment dominated the market with a 56% share, due to the extensive use of genomic technologies in drug discovery clinical trials and development of personalized and precision medicine therapies.
• Clinical Research - The segment accounted for 14% of the total market share, due to disease studies, biomarkers validation and clinical trials enabling faster development of effective and targeted medical treatments.
• Academic & Government Institutes - The segment accounted for 12% of the total market share, due to strong funding for research large scale genome projects and focus on advancing scientific understanding of diseases and genetics.
• Hospitals & Clinics - The segment accounted for 10% of the total market share, due to increasing adoption of genetic testing for diagnosis, personalized treatment planning and improved patient care outcomes
• Other End-Uses - The segment accounted for 8% of the total market share. It includes limited applications in niche areas like forensic studies and agricultural genomics with comparatively lower adoption rates.

Top Companies in the Europe Genomics Market

• Oxford Nanopore Technologies
• Qiagen
• Creative Biogene
• Thermo Fisher Scientific
• Illumina
• Bio-Rad Laboratories
• Danaher Corporation
• Agilent Technologies
• F. Hoffmann-La Roche Ltd.
• Eurofins Scientific Group

Segments Covered in the Report

By Application & Technology

• Functional Genomics
• Epigenomics
• Pathway Analysis
• Biomarker Discovery
• Others

By Deliverables

• Products
• Services

By End-use

• Clinical Research
• Academic & Government Institutes
• Hospitals & Clinics
• Pharmaceutical & Biotechnology Companies
• Other End-uses